Therapy News and Research

RSS

African–American rectal cancer patients wait the longest for treatment

African–American rectal cancer patients wait longer for treatment and are less likely to receive adjuvant chemotherapy than their non-African–American counterparts, results show.

12 Dec 2012

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

Oncogene-induced senescence could play a key role in future cancer therapy

Cell aging, or cellular senescence, has an important role in the natural physiological response to tumor development. Activated oncogenes are able to induce senescence, and recent findings have suggested that oncogene-induced senescence (OIS) could play a key role in future cancer therapy.

12 Dec 2012

Acetazolamide plus autoCPAP may reduce insomnia and control sleep apnea at high altitudes

For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.

12 Dec 2012

Activated astrocytes could play a harmful role in Alzheimer's disease

A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease.

12 Dec 2012

Study identifies KNDy neurons as a likely control switch of hot flushes

Hot flushes affect millions of people, and not just women. Yet, it is still unclear what causes the episodes of temperature discomfort, often accompanied by profuse sweating.

12 Dec 2012

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them. Blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improved adoptive T-cell therapy, an immunotherapy designed to suppress tumor activity.

12 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012

Zucker Hillside Hospital celebrates opening of new $120 million inpatient pavilion

Zucker Hillside Hospital today celebrated the opening of a new 130,000-square-foot, $120 million inpatient pavilion. Constructed with the generous support of North Shore-LIJ Health System trustees Donald and Barbara Zucker and other donors, the 130,000-square-foot building will consolidate outdated living quarters dispersed across the psychiatric facility's campus, significantly improving the coordination of services and treatment along the continuum of care.

12 Dec 2012

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Durata Therapeutics, Inc. today announced preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

11 Dec 2012

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Dementia is the umbrella term used to describe a number of neurodegenerative brain disorders that cause progressive changes in thinking abilities and behaviour. The kind of deficits experienced by individuals diagnosed with dementia depends on the location and severity of the pathology in the brain.

11 Dec 2012

Lenalidomide effective alternative in lupus

The thalidomide derivative, lenalidomide, is a “safe” and effective treatment in refractory cutaneous lupus erythematosus patients, although three-quarters of patients experience clinical relapse after the drug is withdrawn, say Spanish researchers.

11 Dec 2012

Spinal manipulations do not overstrain internal carotid artery

Chiropractic cervical spinal manipulations do not pose undue stress and strain on the internal carotid artery, researchers affirm.

11 Dec 2012

Telestroke networks benefit hospital bank balances

Telestroke networks can increase the number of patients successfully discharged home while saving money for all hospitals involved, show US study results.

11 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Therapy News and Research

African–American rectal cancer patients wait the longest for treatment

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Oncogene-induced senescence could play a key role in future cancer therapy

Acetazolamide plus autoCPAP may reduce insomnia and control sleep apnea at high altitudes

Activated astrocytes could play a harmful role in Alzheimer's disease

Study identifies KNDy neurons as a likely control switch of hot flushes

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Zucker Hillside Hospital celebrates opening of new $120 million inpatient pavilion

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Lenalidomide effective alternative in lupus

Spinal manipulations do not overstrain internal carotid artery

Telestroke networks benefit hospital bank balances

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Studies examine current treatment standards for patients with clotting disorders

Cedars-Sinai first in Los Angeles County to achieve Comprehensive Stroke Center Certification

Some stroke patients may benefit from cerebral angioplasty and stent placement

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News